MARKET

ELTX

ELTX

Elicio Therapeutics, Inc.
NASDAQ
14.20
+0.65
+4.80%
After Hours: 14.10 -0.1 -0.70% 16:26 06/09 EDT
OPEN
13.61
PREV CLOSE
13.55
HIGH
14.20
LOW
12.76
VOLUME
127.12K
TURNOVER
--
52 WEEK HIGH
14.97
52 WEEK LOW
7.37
MARKET CAP
271.02M
P/E (TTM)
-5.8958
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELTX last week (0601-0605)?
Weekly Report · 1d ago
Elicio Therapeutics publishes data on AMP-DNA adjuvant technology
TipRanks · 06/01 14:06
Elicio Therapeutics Announces Publication Of Peer-Reviewed Manuscript In Science Advances Describing Novel AMP-DNA Adjuvant Candidates
Benzinga · 06/01 12:07
Elicio Therapeutics reports preclinical AMP-DNA adjuvant study in Science Advances showing durable T-cell responses
PUBT · 06/01 12:01
Weekly Report: what happened at ELTX last week (0525-0529)?
Weekly Report · 06/01 09:59
Largest borrow rate increases among liquid names
TipRanks · 05/28 15:27
Burns Reiterates Buy on ELI‑002 Program, Maintains $17 Price Target Amid Encouraging Early Efficacy Signals
TipRanks · 05/28 10:26
Largest borrow rate increases among liquid names
TipRanks · 05/27 13:23
More
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Webull offers Angion Biomedica Corp stock information, including NASDAQ: ELTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELTX stock methods without spending real money on the virtual paper trading platform.